S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
MSFT   162.01 (+2.42%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
CGC   18.78 (+1.84%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
T   35.22 (-1.43%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
NFLX   369.03 (-0.72%)
PRI   111.34 (-3.00%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NASDAQ:REPH - Recro Pharma Stock Price, Forecast & News

$14.34
-0.46 (-3.11 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$13.94
Now: $14.34
$14.75
50-Day Range
$14.81
MA: $16.79
$18.78
52-Week Range
$5.53
Now: $14.34
$19.21
Volume325,694 shs
Average Volume275,619 shs
Market Capitalization$325.95 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.31
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.91) per share

Profitability

Net Income$-79,720,000.00

Miscellaneous

Employees255
Market Cap$325.95 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.


Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings results on Friday, November, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $25.26 million for the quarter, compared to analysts' expectations of $19.83 million. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Recro Pharma.

What price target have analysts set for REPH?

3 Wall Street analysts have issued 1-year price targets for Recro Pharma's shares. Their forecasts range from $7.50 to $20.00. On average, they anticipate Recro Pharma's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

Headlines about REPH stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Recro Pharma earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 887,600 shares, a decrease of 18.6% from the January 30th total of 1,090,000 shares. Based on an average trading volume of 327,700 shares, the days-to-cover ratio is presently 2.7 days. Approximately 4.6% of the shares of the stock are sold short. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.48%), Broadfin Capital LLC (3.17%), Panagora Asset Management Inc. (2.10%), Kennedy Capital Management Inc. (1.89%), State Street Corp (1.79%) and Geode Capital Management LLC (1.26%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood and Healthcare Master Fun Broadfin. View Institutional Ownership Trends for Recro Pharma.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Oxford Asset Management LLP, Essex Investment Management Co. LLC, Monarch Partners Asset Management LLC, Penn Capital Management Co. Inc., Walthausen & Co. LLC, Goldman Sachs Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Calamos Advisors LLC, Renaissance Technologies LLC, EAM Global Investors LLC, Prudential Financial Inc., EAM Investors LLC, Russell Investments Group Ltd. and Panagora Asset Management Inc.. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $14.34.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $325.95 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com/.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is the S&P/TSX Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel